Published in Nat Med on August 01, 1999
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol (2007) 2.02
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
SAP-less chromatin triggers systemic lupus erythematosus. Nat Med (1999) 1.16
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J (2001) 4.21
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Role of complement in induction of the allergic response. Nat New Biol (1972) 2.90
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Effect of alcohol consumption on systemic markers of inflammation. Lancet (2001) 2.52
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med (1974) 2.45
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Role of complement in the induction of immunological responses. Transplant Rev (1976) 2.21
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2.10
Amyloidosis. Histopathology (1994) 2.10
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.76
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature (1981) 1.70
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Biology of serum amyloid P component. Ann N Y Acad Sci (1982) 1.65
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet (1988) 1.61
C-reactive protein in SLE. Clin Rheum Dis (1982) 1.61
Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia (1988) 1.60
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J (2004) 1.59
Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med (1980) 1.57
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56
Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med (1981) 1.53
Studies in vivo of cobra factor and murine C3. Immunology (1975) 1.49
Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM (2000) 1.45
Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut (1986) 1.44
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42
C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol (1985) 1.40
Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol (1982) 1.39
Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med (1984) 1.38
Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol (1982) 1.37
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol (1984) 1.36
Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation (1998) 1.36
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation (1998) 1.35
Acute phase response and evolution of familial Mediterranean fever. Lancet (1999) 1.34
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med (1988) 1.34
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem (2000) 1.34
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol (1983) 1.32
Amyloid P-component in human glomerular basement membrane. Abnormal patterns of immunofluorescent staining in glomerular disease. Lancet (1980) 1.32
Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem (1994) 1.31
Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med (1990) 1.30
The genetic basis of autosomal dominant familial Mediterranean fever. QJM (2000) 1.29
Primary localised amyloidosis of the orbit. Br J Ophthalmol (1996) 1.28
Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study. Arthritis Rheum (1985) 1.27
Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta (1991) 1.25
Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med (1995) 1.24
Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol (1986) 1.23
Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. Clin Exp Immunol (1980) 1.23
Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest (1990) 1.22
Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol (1991) 1.22
Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem (1998) 1.22
Enumeration of lymphocyte populations in whole peripheral blood with alkaline phosphatase-labelled reagents. A method for routine clinical use. Clin Exp Immunol (1977) 1.21
An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A. J Immunol Methods (1979) 1.20
SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid (1998) 1.20
Effect of ultraviolet radiation on production of epidermal cell thymocyte-activating factor/interleukin 1 in vivo and in vitro. Proc Natl Acad Sci U S A (1984) 1.18